The aetiology of uterine ®broids remains unknown, despite causing signi®cant gynaecological morbidity. Fibroids have a reduced microvascular density when compared with adjacent myometrial tissue. The aim of this study was to identify genes with differential expression between ®broid and adjacent normal myometrium, particularly genes with a role in angiogenesis. Total RNA was extracted from ®broid/myometrium pairs from 12 hysterectomy specimens, and used to perform 24 cDNA microarrays. There were 10 500 genes screened on each microarray for differential expression. Analysis of expression data was carried out using multiple t-tests, as well as a novel class prediction algorithm (GeneRaVEÔ). The differential gene expression of selected genes was con®rmed by quantitative`real time' RT±PCR. Selected genes with a role in angiogenesis were further analysed for expression in isolated cell populations of endothelial cells (®broid and myometrium) and smooth muscle cells (®broid and myometrium), to see if their expression was con®ned to particular cell types. Twenty-®ve genes with differential gene expression between ®broid and myometrium were identi®ed. Insulin-like growth factor-2, endothelin A receptor, connective tissue growth factor (CTGF), cysteine-rich angiogenic inducer 61 (CYR61) and collagen 4a2 (COL4A2) were con®rmed by RT±PCR. CTGF and CYR61, both angiogenesis promoters, were reduced in expression relative to myometrium. COL4A2, the precursor for an angiogenesis inhibitor, canstatin, was increased relative to myometrium. These three genes display an anti-angiogenic expression pro®le in ®broids relative to myometrium. These ®ndings may explain the reduced microvascular density seen in ®broids relative to myometrium.
Introduction
Leiomyomata, or uterine ®broids, are the most common solid tumour to af¯ict women during their reproductive years (Vollenhoven, 1998) . Fibroids are the most frequent indication for hysterectomy in Australia and the US (Treloar et al., 1999; Farquhar and Steiner, 2002) , making them a signi®cant and costly gynaecological problem.
Many differences have been observed between ®broids and myometrium in an attempt to explain ®broid growth, including different levels of peptide growth factors, chromosomal aberrations and subsequent gene changes, and different levels of sex steroid hormone receptors (reviewed by Anderson, 1998) . Despite these observations, the precise aetiology of uterine ®broids has proven dif®cult to elucidate.
One interesting histopathological feature of ®broids is the difference in their vasculature relative to the adjacent myometrium. Reports on the vasculature of ®broids have been scant in the literature, despite the fact that uterine artery embolization via the femoral artery has been used for >20 years to treat ®broids (Abbott et al., 2002) . Fibroids have recently been shown to have a smaller vascular area and microvessel density than adjacent myometrium (Casey et al., 2000; Poncelet et al., 2002) . This is intriguing, as solid tumours have long been postulated to require increased microvessel density in order to support a growth in tumour mass (Folkman, 1998) . Fibroids may behave differently because they are benign tumours. Nonetheless, although a reduced vascular density has been observed in ®broids compared with adjacent myometrium, the factor or factors responsible for this remain unknown.
DNA microarrays are one of an increasing number of tools available for screening for gene expression changes in up to several thousand genes at once (Lander, 1999) . DNA microarrays have advantages over older techniques such as differential display (Pambuccian et al., 2002; Wu et al., 2002) as they provide quantitative as well as qualitative data. One of the major hurdles in the use of microarrays has been the complexity of the statistical analysis of the large datasets generated (Smyth et al., 2002) . Several software programs to assist in the analysis of microarray data have become commercially available, at prices increasingly within the reach of the academic sector.
Both differential display (Pambuccian et al., 2002; Wu et al., 2002) and microarrays (Tsibris et al., 2002) have been used successfully to examine gene expression differences between ®broid and myometrium. The aim of our study was to examine gene expression changes between ®broids and adjacent myometrium from hysterectomy specimens, using cDNA microarrays. Our hypothesis was that the reduced vasculature in the ®broid, when compared with the adjacent myometrium, would be re¯ected in differences in transcriptional activity in genes with a role in angiogenesis. Therefore, we wanted to examine changes in angiogenesis-related genes, in particular, between ®broid and adjacent myometrium.
Materials and methods

Sample collection
Ethical approval for the study was obtained from Southern Health Human Research and Ethics Committee B, and informed consent was obtained from all patients.
Samples of ®broid and adjacent normal myometrium were excised from a total of 28 uteri (mean age 44.3 years, range 33±54) at hysterectomy, and immediately frozen on dry ice. Fibroids sampled were >3 cm in diameter and from the inner third of the myometrium. Tissue sampling from the ®broids was random, without systematically favouring the inner or outer portion of the ®broids. The myometrium sampled was from the inner third of the myometrium. Twelve of the paired samples were used for the microarrays, 18 for the quantitative RT±PCR, and six for tissue culture, with some degree of overlap between the three groups where there was suf®cient tissue collected. All hysterectomy specimens were from pre-menopausal women undergoing operations for ®broids. Tissue samples were only taken from women who had not received exogenous hormones for the previous 3 months.
RNA extraction
Thin shavings of the frozen specimens were homogenized in Trizol reagent (Invitrogen Life Technologies, Australia) according to the manufacturer's protocol. Total RNA was precipitated from the aqueous phase of the Trizol preparation with an equal volume of 100% ethanol, and then run through a Qiagen RNeasy column (Qiagen, Germany) according to the manufacturer's protocol for clean-up of the RNA. After resuspension in RNase-free water, RNA was further treated with an overnight ethanol precipitation as previously described (Weston et al., 2002) . The ®nal concentration of total RNA was 5 mg/ml, required for the cDNA labelling process of the microarray experiments.
cDNA microarrays
The total RNA samples were used to prepare¯uorescent-labelled cDNA for probing with glass microarray slides spotted with 10 500 human cDNA sequences (prepared in-house at the Peter MacCallum Cancer Institute Microarray Facility, Melbourne, Australia; the complete list of genes on the array is available at www.CCGPM.org). 60±90 mg of total RNA was used for each microarray, with an equal amount of reference total RNA used as the control. A direct-labelling procedure was used for creating¯uorescent-labelled cDNA. The labelling and hybridization of the slides has been described previously (Weston et al., 2002) .
A total of 24 microarrays were performed. In the ®rst 12 arrays, individual ®broid RNA specimens were labelled with the experimental¯uorescent dye Cy5 (cat. no. PA55201; Amersham Bioscience, UK). These were run against an aliquot of reference myometrial RNA labelled with Cy3 dye (cat. no. PA53201; Amersham). The reference myometrial RNA was formed from groups of six myometrial samples. In the second group of 12 arrays, individual myometrial RNA specimens were labelled with the experimental dye, and run against a reference pool of ®broid RNA specimens (again, two groups of six ®broid samples were used to form the reference RNA). This experimental design incorporated a dye-swap (Sterrenburg et al., 2002) , to ensure that genes identi®ed were up-or down-regulated regardless of which of the two dyes was used to label the RNA. The design also provided quantitative gene expression data on each of the 24 separate biological samples (12 pairs of ®broid and myometrium samples).
Slides were scanned using a dual UV-laser GSI Luminomics scanner (Packard Bioscience, USA) and¯uorescent intensity analysed using the program Quantarray (Packard Bioscience). Images were formed by superimposing the Cy3 and Cy5 images for each slide using the Scanalyze software (M.Eisen, Brown Lab, Stanford, USA). Two of the arrays with myometrial RNA labelled with the Cy5 dye were excluded, due to poor image quality.
Normalization of data from the remaining 22 arrays was carried out using Genespring (Silicon Genetics, USA). Raw Quantarray data were logtransformed, and subsequent intensity-dependent normalization achieved by use of a Lowess ®t. The Lowess ®t adjusts for differential labelling ef®ciency of the two¯uorescent dyes. Normalized values <0 were set to 0, and data for individual genes were rejected if the background-subtracted control value was <10.0. The Cy5 (experiment)¯uorescent intensity was divided by the Cy3 (reference) intensity for each gene to give a gene expression level relative to reference for each of the 10 500 genes. Statistical analysis was carried out as described below.
Quantitative RT±PCR
One mg total RNA from each sample to be analysed by RT±PCR was DNasetreated using the DNA-free kit (Ambion, USA) according to the manufacturer's protocol, then reverse-transcribed at 42°C for 1 h in a total volume of 20 ml (2.5 ml anchor primer oligodT 15 ; Roche, Australia), 2 ml 10 mmol/l dNTP (Roche), 4 ml 5QRT buffer (Roche), 0.5 ml RNasin (Promega, USA), 2 ml dithiothreitol (Promega), 0.2 ml AMV reverse transcriptase (Roche), total RNA and sterile H 2 O to make up the volume). Two ml of a 1:10 dilution of the RT product was used as a template for the subsequent PCR.
Roche LightCycler was used to perform quantitative PCR. For a detailed overview of the principles of the technique see Drummond et al. (2000) . Reagents for the LightCycler PCR were obtained from Roche. The primer sequences used are shown in Table I . Primer concentrations were 0.5 mmol/l. Each set of primers was optimized for magnesium concentration, annealing temperature and extension time as shown in Table II . Relative levels of mRNA expression for each of the genes tested were determined by measurement against a speci®c cDNA standard. All results were normalized against a Ã-actin expression to correct for differences in concentration of the starting template.
Tissue culture and RNA samples of separate cell populations from ®broid and myometrium Total RNA was extracted from myometrial and ®broid microvascular endothelial cells (MEC) and smooth muscle cells (SMC) cultured from a further set of six myometrium±®broid tissue pairs as previously described (Gargett et al., 2002) . These cultures were from passages 1±3. They were also >98% pure for each cell type as determined by¯ow cytometric analysis for CD31 and alpha smooth muscle actin for MEC and SMC respectively as detailed previously (Gargett et al., 2002) .
Statistical analysis
Genespring was used to identify genes with statistically signi®cant differential expression by performing t-tests with multiple test correction using the Benjamini±Hochberg false discovery rate (Benjamini and Hochberg, 1995) . Signi®cance tests were performed on Lowess-normalized data (see above). Genes with P < 0.05 after multiple test correction were considered signi®cant if they were differentially expressed by a factor of b1.5 in b80% of the replicates. The 1.5-fold threshold was chosen arbitrarily to focus on genes likely to have biologically signi®cant as well as statistically signi®cant gene expression changes.
The microarray data were examined via a second technique, components from a suite of statistical algorithms developed by the Bioinformatics Technology Group (CSIRO, Mathematical and Information Sciences), called GeneRaVEÔ, to identify differentially expressed genes. GeneRaVEÔ may be characterized as Bayesian stochastic variable selection. The validation strategy of GeneRaVEÔ uses permutation distributions and cross-validation. This strategy has been validated on public domain microarray data sets such as the B-cell lymphoma data of Alizadeh et al. (2000) and the prostate cancer data of Luo et al. (2001) . In one of its formulations, GeneRaVE is able to obtain parsimonious sets of solution genes as sample classi®ers. The solution sets may be validated by the magnitude of the proportion of misclassi®cations generated by the set, by subsequent permutation tests, and by solution stability tests such as leave-out-one-sample-at-a-time procedures.
For the data of the current paper, GeneRaVEÔ was ®rst run using every microarray with the full complement of probe genes. The solution genes identi®ed by GeneRaVEÔ in this step were placed in the initial gene solution set. Next, in a leave-out-one-sample-at-time procedure, GeneRaVEÔ was run using all arrays except for the ®rst array, then using all arrays except the second and so on, ®nishing with running GeneRaVEÔ on all arrays except for the last array. At each run, a solution set of genes was obtained. This procedure provided a test of solution stability and had the potential to identify other solution genes. GeneRaVEÔ was then reapplied to the microarray data with the microarray data of all the solution set genes eliminated. Although repeated applications of GeneRaVEÔ in this fashion has the potential to generate many solution genes for group classi®cation, it was decided to repeat this procedure until 25±30 solution genes were obtained. This procedure generated a`league table' for ranking all the solution genes obtained by successive reapplications of GeneRaVEÔ.
Following the statistical analyses outlined, a list of genes (Table III) on the microarray with a known role in angiogenesis was created, following a literature search. The list of genes was examined to see if their expression varied between ®broid and adjacent myometrium.
Quantitative gene expression data from the LightCycler were analysed by either paired t-tests (®broid versus myometrium pairs), or by one-way analysis of variance (matched sets of four cell populations).
Results
cDNA microarrays
A total of 25 genes was identi®ed as being differentially expressed between ®broid and myometrium by at least one of the two statistical analysis methods (Table IV) . Of the genes identi®ed, 11 displayed a lower expression in ®broids than in the adjacent myometrium, while 14 showed higher expression than the adjacent myometrium. Of the 25 genes identi®ed, 10 (40%) had previously been reported (Table IV) .
Genespring identi®ed 11 genes, ®ve of which (45.5%) had been previously reported, while GeneRaVEÔ identi®ed 23 genes, with nine (39%) previously reported. The Genespring list had only two genes not identi®ed by the GeneRaVEÔ analysis, while the GeneRaVEÔ list had 14 extra genes.
In a further analysis, we divided ®broid and myometrial specimens based on the stage of the menstrual cycle (proliferative or secretory phase). We found no signi®cant differences in gene expression between proliferative and secretory phase ®broid or myometrium. There were only half as many samples in each of the groups when divided on the basis of the phase of the menstrual cycle, reducing the power of this further analysis to detect gene expression changes.
Angiogenesis-associated genes by microarray
Of the genes identi®ed from the analysis, three have been implicated in angiogenesis. CYR61 (cysteine-rich angiogenic inducer 61) (Babic et al., 1998) and CTGF (connective tissue growth factor) (Babic et al., 1999) are both angiogenesis promoters which were down-regulated in ®broids compared with myometrium in our arrays. Collagen 4a Â2 (COL4A2) is a precursor for the angiogenesis inhibitor, canstatin (Kamphaus et al., 2000) , and was up-regulated in ®broid compared with adjacent myometrium.
We went on to examine the expression of angiogenesis promoters and angiogenesis inhibitors present in the group of 10 500 genes present on our microarrays (Table III) in pairs of ®broid and adjacent myometrium. We compared their expression pro®le to that of the three angiogenesis modulators above. There did not appear to be any signi®cant differences in the expression pro®le of any of the angiogenesis promoters (see Figure 1A ,B) or inhibitors (see Figure 1C ,D) between ®broid and myometrium, other than the three genes already identi®ed: CYR61, CTGF and COL4A2.
The expression pattern of the three angiogenesis-related genes (CYR61, CTGF and COL4A2) are represented graphically in three dimensions in Figure 2 . This triad of angiogenesis-related genes displays an anti-angiogenic pro®le in ®broids when compared with adjacent myometrium (reduced expression of CYR61 and CTGF, and increased expression of COL4A2).
Quantitative RT±PCR for con®rmation of selected genes identi®ed by microarray Con®rmation of selected genes identi®ed in our analysis was performed using`real time' quantitative RT±PCR. Insulin-like growth factor-2 (IGF-2) and endothelin A receptor (ET-A R) were assessed ( Figure 3 ) in addition to CYR61, CTGF and COL4A2 (Figure 4 ). For all ®ve of the genes, the gene expression microarray result was con®rmed. RT±PCR performed on 18 pairs (®broid and myometrium from the same uterus) produced statistically signi®cant gene expression differences by paired t-test. The speci®c levels of signi®cance for each of the genes tested were IGF-2 (P = 0.0027), ET-A R (P = 0.0287), CYR61 (P = 0.0089), CTGF (P = 0.0307), and COL4A2 (P = 0.002). The fold-change in gene expression was in all cases underestimated by the microarray. There was considerable variation amongst the different ®broids in gene expression relative to their adjacent myometrium as measured by RT±PCR. CYR61 mRNA was down-regulated by b1.5-fold in ®broids compared with adjacent myometrium in 13/18 pairs, but in 5/18 pairs CYR61 mRNA levels in ®broids were equivalent to myometrium expression (<1.5-fold different in expression). In no ®broid±myometrium pairs was CYR61 expression up-regulated by b1.5-fold in the ®broid tissue. CTGF showed more variation than CYR61 in differential gene expression between different pairs. In 11/18 pairs, CTGF expression was down-regulated b1.5-fold in ®broids, but in 4/18 pairs, there was actually up-regulation b1.5-fold in ®broids, and in 3/18 CTGF expression was equivalent (<1.5-fold difference). COL4A2 also showed variation on an individual basis, despite the statistically signi®cant overall trend to increased expression in ®broids. Eleven of the 18 pairs showed up-regulation in ®broids by b1.5-fold, but 6/18 showed equivalent expression (<1.5-fold difference between ®broid and myometrium expression) and 1/18 had down-regulation in ®broid, by >1.5-fold. Examining the gene expression changes of all ®ve genes according to the phase of the menstrual cycle of the samples (proliferative or secretory phase), again we could ®nd no statistically signi®cant gene expression changes. Six of the 18 samples were proliferative phase, six were secretory, and on six samples we had no information on cycle phase. Only CYR61 showed any trend to alteration in gene expression across the cycle. There was a trend to increased expression in the myometrium in the proliferative phase of the cycle (mean in proliferative phase 1.88 relative units, mean in secretory phase 0.69 relative units, with P = 0.084 by t-test). This trend was not evident in the ®broid (mean in proliferative phase 0.51 relative units, mean in secretory phase 0.36 relative units, P = 0.29 by t-test)
CYR61, CTGF and COL4A2 expression in separate cell populations
Total RNA was obtained from cultured myometrial microvascular endothelial cells (MMEC), ®broid myometrial microvascular endothelial cells (FMEC), myometrial smooth muscle cells (MSMC) and ®broid smooth muscle cells (FSMC) from another six hysterectomy specimens. The separate cell populations were assessed for their mRNA levels of CYR61, CTGF and COL4A2 by quantitative RT±PCR (Figure 5) , to determine the cell types expressing these three angiogenesis modulators. All four cell types expressed each of the three angiogenesis modulators in vitro, and the differences in levels of mRNA expression for all three genes was not signi®cant. However, the highest expression of the angiogenesis promoters CYR61 and CTGF was in MMEC.
Discussion
This is the largest set of gene expression microarrays of ®broids to be reported in the literature to date, and identi®es a total of 25 differentially expressed genes between ®broid and myometriumÐ15 of them not previously reported. It is the ®rst report in the microarray literature to employ a novel new statistical algorithm, GeneRaVEÔ, for identifying genes with different expression patterns in two populations. This work identi®es for the ®rst time a set of three angiogenesis-related genesÐCYR61, CTGF and COL4A2Ðwith an anti-angiogenic gene expression pro®le in ®broids when compared with adjacent normal myometrium.
The only microarray study published to date (Tsibris et al. 2002) used nine paired hysterectomy specimens in a set of nine arrays, and identi®ed 145 genes on the basis of fold-changes in gene expression between ®broids and adjacent myometrium. The smaller number of genes identi®ed in our study was due in part to the stringency of the analysis methods employed, as well as to the inherently high variability of ®broids. Using statistical tests for signi®cance with multiple test correction reduces the number of genes identi®ed, but increases the true positive rate of the genes that are identi®ed (Smyth et al., 2002) . Many array studies in the reproductive literature currently use fold-changes in gene expression as a threshold when identifying genes (Tsibris et al., 2002; Weston et al., 2002) , often identifying very large gene sets. The advantage from an increase in number of genes is likely to be offset by an increase in the false positive rate, making subsequent con®rmation by other experimental methods essential. The CCN gene family was named after the ®rst three known members: CTGF, NOVH (nephroblastoma overexpressed gene) and CYR61 (Bork et al., 1993) . Members of this gene family encode secreted proteins which modulate the actions of growth factors, and affect cell migration and extracellular matrix production (Brigstock, 1999) . Both CTGF and CYR61 are promoters of angiogenesis (Babic et al., 1998; . CYR61 has been shown to induce neovascularization in vivo, and chemotaxis of microvascular endothelial cells in vitro (Babic et al., 1998) . CTGF has been shown to have multiple actions on human microvascular endothelial cells in vitro which stimulate angiogenesis, including endothelial cell proliferation, adhesion, migration, as well as reducing apoptosis and promoting endothelial cell survival (Babic et al., 1999) . This is the ®rst study to show altered expression of the angiogenic inducer CTGF in ®broids. We identi®ed CTGF as a differentially expressed gene with reduced expression in ®broid compared with myometrium. This was con®rmed on subsequent quantitative PCR. The only other study to examine CTGF in human ®broids found CTGF protein con®ned to the endothelial cells, but did not attempt to quantify differences in expression (Uzumcu et al., 2000) .
CYR61 has been reported in one study to be reduced in ®broid compared with adjacent myometrium (Sampath et al., 2001) . Our work con®rms these results. However, we extended our analysis to examine gene expression in separate cell populations, and found that microvascular endothelial cells as well as smooth muscle cells express CYR61 mRNA. This is in contrast to the study by Sampath et al., which did not detect CYR61 mRNA in microvascular endothelial cells by in-situ hybridization. Whether the increased CTGF and CYR61 gene expression in myometrium is from the smooth muscle cell or Three-dimensional plot of the normalized gene expression ratios for each of the three angiogenesis-related genes (CYR61, CTGF and COL4A2) in each of the 12 ®broid and 10 myometrium arrays analysed. Each myometrial sample (M) is plotted as a ratio of the combined ®broid reference in each of three dimensions corresponding to each of the three angiogenesis-related genes. Each ®broid (F) sample is plotted as a ratio of the combined myometrium reference, again in three dimensions for the three angiogenesis genes. Both the ®broid and myometrium specimens are clearly separated into separate groups. Figure 3 . Levels of mRNA expression in 18 paired ®broid and myometrial specimens as determined by quantitative RT±PCR for the genes IGF-2 and endothelin A receptor (ET-A R). In both, the microarray result was con®rmed. mRNA levels in arbitrary units are shown on the y-axis of the graphs, with all results corrected against expression of the housekeeping gene a Ã-actin (²P < 0.05; *P < 0.01). Graphs on the left are line graphs linking paired specimens, those on the right are box-and-whisker plots. Figure 4 . Levels of mRNA expression in 18 paired ®broid and myometrial specimens as determined by quantitative RT±PCR for the three genes CYR61, CTGF and COL4A2. In all three, the microarray result was con®rmed. mRNA levels in arbitrary units are shown on the y-axis of the graphs, with all results corrected against expression of the housekeeping gene a Ã actin (²P < 0.05; *P < 0.01). Graphs on the left are line graphs linking paired specimens, those on the right are box-and-whisker plots. endothelial cell population is uncertain, as our quantitative RT±PCR on separated cell types in culture showed no signi®cant differences ( Figure 5 ). If the endothelial cells are the source of the difference in expression, it is possible that the differences are due to the in¯uence of the different microenvironments of the microvascular endothelial cells within the ®broid (surrounded by an extensive extracellular matrix) compared with the myometrium.
COL4A2 gene encodes collagen 4a Â2, a basement membrane component associated ubiquitously with blood vessels. Canstatin, a 24 kDa fragment of collagen 4a Â2, has been shown to be an angiogenesis inhibitor (Kamphaus et al., 2000) . In this study, we have shown for the ®rst time that the COL4A2 gene is overexpressed in ®broid compared with myometrium. This may indicate that there is greater production and breakdown of collagen 4a Â2 in ®broids, generating more of the angiogenesis inhibitor canstatin in ®broids than in myometrium. At present, however, it is unknown if canstatin is produced in ®broids.
Our data show reduced expression of two recently identi®ed angiogenesis promoters, and overexpression of the precursor of an angiogenesis inhibitor. The expression pro®les of these three genes display an anti-angiogenic pro®le which may explain in part the reduced microvessel density observed in ®broids compared with myometrium (Casey et al., 2000) .
Although this study has concentrated on CTGF and CYR61 with regard to their ability to promote angiogenesis, these two factors are known to have multiple biological actions (Brigstock, 1999) . Through their actions on cell cycle regulation, cell adhesion and migration and production of extracellular matrix, they play a role in the growth of a variety of tumours, including breast cancer (Brigstock, 1999) . In in¯ammation and wound repair, they are also postulated to play an important role. Paradoxically in a tumour such as a ®broid, characterized by increased extracellular matrix, CTGF is underexpressed in ®broid compared with adjacent myometrium. CTGF is overexpressed in a large number of pathological conditions characterized by ®brosis, including skin conditions such as scleroderma and keloid (Igarashi et al., 1996) , and diseases of the lung such as pulmonary ®brosis (Phan and Kunkel, 1992) . The underexpression of CTGF in ®broids despite the increased extracellular matrix highlights the current gaps in our understanding of the CCN family of proteins and the precise role they play in ®broid growth.
IGF-2 and ET-A R were two other genes identi®ed in our arrays and con®rmed by quantitative PCR. Overexpression of IGF-2 in ®broids compared with myometrium has been previously reported (Vollenhoven et al., 1993) . Our study con®rmed this. The overexpression of endothelin-A receptor in ®broids relative to myometrium has also been previously reported (Pekonen et al., 1994) .
In this study, we utilized two statistical algorithms for identifying genes. One of those algorithms, Genespring, identi®ed 11 genes by ttests with multiple test corrections. Genespring is a powerful tool for visualizing gene expression data from DNA microarrays, and has been used to analyse microarray data from human endometrium (Kao et al., 2002) . We also used a novel class prediction algorithm called GeneRaVEÔ, which identi®es parsimonious gene sets that de®ne different groups of data. It should be noted that the two statistical methods work by different statistical approaches. However, despite this, all but two of the genes from the Genespring list also appeared in the GeneRaVEÔ list. Five of the genes we identi®ed from the gene lists were subsequently all con®rmed by quantitative RT±PCR.
Fibroids have a reduced microvessel density compared with adjacent myometrium. This study identi®es three genes with altered expression in ®broids which may explain this reduction in microvascular density. How the vessel density relates to ®broid tumour growth and progression is uncertain. It may be that the secreted proteins with dysregulated expression in ®broids may affect ®broid tumour growth via modulation of the stimulus of other growth factors such as bFGF (Brigstock et al., 1999) . More work is required on members of the CCN family in ®broids to examine their potential role in ®broid growth, and in particular, in angiogenesis within ®broids.
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